NASDAQ: IONS - Ionis Pharmaceuticals

Yield per half year: -27.78%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Ionis Pharmaceuticals

Extended chart Simple chart
Financial Markets by TradingView

About Ionis Pharmaceuticals

Ionis Pharmaceuticals - биотехнологическая компания, базирующаяся в Карлсбаде, Калифорния, которая специализируется на открытии и разработке терапевтических средств, нацеленных на РНК. У компании есть 3 коммерчески одобренных препарата: Спинраза (Нусинерсен), Тегседи (Инотерсен) и WAYLIVRA, а также 4 препарата в основных исследованиях: томинерсен от болезни Хантингтона, тоферсен от SOD1-ALS, AKCEA-APO (a) -LRx от сердечно-сосудистых заболеваний. и AKCEA-TTR-LRx для всех форм амилоидоза TTR. До декабря 2015 года компания носила название Isis Pharmaceuticals.

more details
Компания была основана в 1989 году как Isis Pharmaceuticals Стэнли Т. Крук, бывшим руководителем отдела исследований GlaxoSmithKline, с целью коммерциализации антисмысловой терапии.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1991-05-17
ISIN US4622221004
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 3.16
Дивиденд ао 0.66
Сайт http://www.ionispharma.com
Цена ао 32.27
Change price per day: +4.46% (26.71)
Change price per week: +2.99% (27.09)
Change price per month: -16.49% (33.41)
Change price per 3 month: -16.62% (33.46)
Change price per half year: -27.78% (38.63)
Change price per year: -33.16% (41.74)
Change price per 3 year: -18.04% (34.04)
Change price per 5 year: -50.41% (56.26)
Change price per 10 year: -15.53% (33.03)
Change price per year to date: -25.96% (37.68)
All parameters

Underestimation

Title Value Grade
P/S 7.4 1
P/BV 8.87 1
P/E 122.59 1
EV/EBITDA -13.44 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -15.15 0
ROE, % -93.1 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.625 6.25
Total: 2.23

Debt

Title Value Grade
Debt/EBITDA -2.96 10
Total: 8.4

Growth impulse

Title Value Grade
Yield Revenue, % -3.27 0
Yield Ebitda, % 176.21 10
Yield EPS, % -13.01 0
Total: 4
More

Institutions Volume Share, %
FMR, LLC 21520872 14.77
Vanguard Group Inc 14203481 9.74
T. Rowe Price Investment Management, Inc. 13201453 9.06
Blackrock Inc. 9057530 6.21
Bellevue Group AG 8713987 5.98
ClearBridge Investments, LLC 4707480 3.23
Wellington Management Group, LLP 4616978 3.17
Price (T.Rowe) Associates Inc 4255074 2.92
State Street Corporation 4008797 2.75
Pictet Asset Management Holding SA 3518317 2.41

ETFShare, %Profitability for 1 year, %Dividends, %
Direxion mRNA ETF 4.07 0
Future Tech ETF 0.61003 426.34 0.8416
Principal Healthcare Innovators ETF 0.61003 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.25021 596.94 0.72598
Fidelity Growth Opportunities ETF 0.2118 -1.24 0.48881
iShares Morningstar Small-Cap ETF 0.12527 391.25 1.60498
0.98338.630.75



Head Job title Payment Year of birth
Mr. Darren Gonzales Chief Accounting Officer & Senior VP N/A
Dr. Brett P. Monia Ph.D. Founder, CEO & Director 1.71M 1961 (64 years)
Ms. B. Lynne Parshall Esq., J.D. Director 334.64k 1954 (71 year)
Dr. C. Frank Bennett BSc, Ph.D. Executive VP & Chief Scientific Officer 651.64k 1957 (68 years)
Mr. D. Wade Walke Ph.D. Senior Vice President of Investor Relations N/A
Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. Executive VP of Finance & CFO 1.02M 1962 (63 years)
Dr. Richard S. Geary Ph.D. Executive VP & Chief Development Officer 946.26k 1958 (67 years)
Ms. Hayley Soffer Vice President of Corporate Communications N/A
Dr. Eric E. Swayze Ph.D. Executive Vice President of Research 1966 (59 years)
Mr. Patrick R. O'Neil Esq. Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary 1974 (51 year)

Address: United States, Carlsbad, 2855 Gazelle Court - open in Google maps, open in Yandex maps
Website: http://www.ionispharma.com